Literature DB >> 25863488

Serum aminotransferase levels and angiographic coronary artery disease in octogenarians.

Shivank A Madan1, Dinesh Singal2, Snehal R Patel3, C S Pitchumoni4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25863488     DOI： 10.1007/s12020-015-0595-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  19 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction.

Authors:  J S LADUE; F WROBLEWSKI; A KARMEN
Journal:  Science       Date:  1954-09-24       Impact factor: 47.728

3.  The association of the Friesinger score and pulse pressure in an urban South Asian patient population: pulse pressure, an independent predictor of coronary artery disease.

Authors:  Fahad Javed; Emad F Aziz; Girish N Nadkarni; Shahzeb A Khan; Manpreet Singh Sabharwal; Rishi Malhan; Alexandre Benjo; Eyal Herzog; Franz H Messerli
Journal:  J Am Soc Hypertens       Date:  2010 May-Jun

4.  Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males.

Authors:  Rui Wang; Qiang Lu; Ji Feng; Fuzai Yin; Chunmei Qin; Bo Liu; Yali Liu; Xiaoli Liu
Journal:  Endocrine       Date:  2011-07-28       Impact factor: 3.633

5.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

Authors:  Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant
Journal:  Atherosclerosis       Date:  2006-05-08       Impact factor: 5.162

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 7.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

8.  Prediction of coronary atherosclerotic disease with liver transaminase level.

Authors:  Peyman Adibi; Masoumeh Sadeghi; Majid Mahsa; Golnaz Rozati; Masood Mohseni
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

9.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

10.  Framingham risk score and prediction of lifetime risk for coronary heart disease.

Authors:  Donald M Lloyd-Jones; Peter W F Wilson; Martin G Larson; Alexa Beiser; Eric P Leip; Ralph B D'Agostino; Daniel Levy
Journal:  Am J Cardiol       Date:  2004-07-01       Impact factor: 2.778
View more
  1 in total

1.  ALT-to-Lymphocyte Ratio as a Predictor of Long-Term Mortality in Patients with Normal Liver Function Presenting Coronary Artery Disease after Undergoing PCI: A Retrospective Cohort Study.

Authors:  Ru-Jie Zheng; Qian-Qian Guo; Jun-Nan Tang; Xu-Ming Yang; Jian-Chao Zhang; Meng-Die Cheng; Feng-Hua Song; Zhi-Yu Liu; Kai Wang; Li-Zhu Jiang; Lei Fan; Xiao-Ting Yue; Yan Bai; Xin-Ya Dai; Zeng-Lei Zhang; Ying-Ying Zheng; Jin-Ying Zhang
Journal:  J Interv Cardiol       Date:  2020-04-21       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.